June 25, 2019 / 12:37 PM / a month ago

FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder

June 25(Reuters) - Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.

The treatment, Edsivo, aims to treat vascular Ehlers-Danlos syndrome - the most severe type of a hereditary disorder of the connective tissue. (Reporting by Manojna Maddipatla and Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below